By Sheeba M. | April 13, 2026
Trulieve Reports Strong Q1 2026 Revenue, Eyes National Expansion
Trulieve Cannabis Corp. (NASDAQ: TCNNF) delivered a solid first quarter, reporting revenue of $290 million against Wall Street expectations of $268 million. The Florida-based multi-state operator posted adjusted EBITDA of $45 million, representing a 15.5% margin that signals improving operational efficiency across its 87 dispensary footprint.
Revenue Growth Driven by Pennsylvania and Ohio
The company’s strategic expansion into Pennsylvania and Ohio medical markets continues to bear fruit. Same-store sales grew 12% year-over-year, while the average transaction size increased to $67 from $58 in the prior year period. Trulieve’s vertical integration model—cultivating 85% of its own product—provides pricing leverage that smaller competitors cannot match.
CEO Kim Rivers highlighted that the company processed over 1.2 million transactions in Q1, with flower products representing 55% of revenue and concentrates growing to 28%. The remaining 17% came from edibles and topical products, showing balanced portfolio diversification.
Balance Sheet Strength for Federal Rescheduling
Trulieve ended Q1 with $215 million in cash and manageable debt of $380 million. The company’s current ratio of 2.1 suggests adequate liquidity to pursue opportunistic acquisitions should federal cannabis reform create M&A opportunities. Management reiterated its full-year guidance of $1.15-$1.25 billion in revenue.
Investors will note that Trulieve’s tax asset carryforwards total approximately $180 million, which could provide significant EPS upside onceSAFE Banking Act passage removes Section 280E tax penalties that currently reduce after-tax margins by an estimated 40%.
Outlook and Key Catalysts
The company expects to open 8-10 new dispensaries in Florida during 2026 while maintaining its position as the state’s largest operator with 61 locations. Pennsylvania expansion remains a priority, with three new locations scheduled for Q2 opening in the Pittsburgh and Philadelphia metro areas.
For investors, the key question is whether Trulieve can maintain its margin profile while investing in growth markets. Current valuation at 1.2x forward EV/Revenue looks attractive given the company’s盈利能力和federal rescheduling optionality. The stock remains a core holding for cannabis sector exposure, particularly for investors focused on MSO earnings season.
Sources
- SEC EDGAR – Trulieve Filings — Q1 2026 earnings press release and 10-Q filing
- Bloomberg Terminal — Consensus estimates and valuation metrics
- IRS Section 280E Guidance — Tax implications for cannabis companies
Track cannabis stocks with the Weedstock Real-Time Tracker